Content Area

Stop tadalafil tablets at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)]. The recommended dose of tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food.

Feature	Description	Appearance Details	Special Characteristics
Embedded Gem-like Accents	Sometimes embedded decorative elements	Glittering or metallic look	Exotic appeal, not typical
Limited Edition Color	Rare colors or patterns	Striking visuals, holographic effects	Collector's item
Branding Logos	Custom logo embossing	Prominent, elaborate designs	High-quality imprinting

Dividing the dose (40 mg) over the course of the day is not recommended.

17.7 Sudden Hearing Loss

There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labelling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil 40 mg was 4% compared to 5% in placebo-treated patientsIn the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity.

Alcohol and Cialis

Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations (8.6)] . Mild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day. Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied.

Product	Dosage	Quantity + Bonus	Price
Cialis Professional	20mg	10 Pills	48.29€ 45.99€	Buy
Cialis Generic	10mg	60 + 6 Pills	105.81€ 100.77€	Buy
Cialis Professional	20mg	90 + 2 Pills	241.49€ 229.99€	Buy
Cialis Professional	40mg	30 Pills	148.94€ 141.85€	Buy
Cialis Generic	2.5mg	10 Pills	28.51€ 27.15€	Buy
Cialis Black	80mg	360 + 20 Pills	639.78€ 609.31€	Buy
Cialis Original	20mg	8 Pills	61.70€ 58.76€	Buy
Cialis Generic	5mg	270 + 10 Pills	205.81€ 196.01€	Buy
Cialis Generic	5mg	30 + 4 Pills	53.56€ 51.01€	Buy
Cialis Original	20mg	4 Pills	41.99€ 39.99€	Buy
Cialis Professional	40mg	10 Pills	65.09€ 61.99€	Buy
Cialis Original	20mg	64 + 4 Pills	274.18€ 261.12€	Buy
Cialis Professional	20mg	20 Pills	78.33€ 74.60€	Buy
Cialis Generic	60mg	30 + 2 Pills	85.33€ 81.27€	Buy
Cialis Generic	40mg	90 + 6 Pills	171.35€ 163.19€	Buy
Cialis Black	80mg	270 + 10 Pills	502.88€ 478.93€	Buy
Cialis Professional	40mg	90 + 2 Pills	348.59€ 331.99€	Buy

Avoid use of tadalafil tablets [see Use in Specific Populations (8.7)] . Co-administration of Tadalafil Tablets in Patients on Ritonavir In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. Co-administration of Ritonavir in Patients on Tadalafil Tablets Avoid use of tadalafil tablets during the initiation of ritonavir.

5.1 Cardiovascular

Do not use nitrates within cialis soft online 48 hours of the last dose of tadalafil tablets. Tadalafil potentiates the hypotensive effect of nitrates.This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)].4.2 Concomitant Guanylate Cyclase (GC) StimulatorsCoadministration of GC stimulators such as riociguat with tadalafil tablets is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.4.3 Hypersensitivity ReactionsTadalafil tablet is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or CIALIS). Tadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Tadalafil potentiates the hypotensive effect of nitrates.This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)].

Erectile Dysfunction

Coadministration of GC stimulators such as riociguat with tadalafil tablets is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators. Tadalafil tablet is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or CIALIS). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects.

Professional resources

Patients with pre-existing hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of tadalafil to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended. Should signs of pulmonary edema occur when tadalafil tablet is administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged ≥50 in the general population. 4 CONTRAINDICATIONS 4.1 Concomitant Organic NitratesTadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Do not use nitrates within cialis soft online 48 hours of the last dose of tadalafil tablets. Tadalafil potentiates the hypotensive effect of nitrates.This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)].4.2 Concomitant Guanylate Cyclase (GC) StimulatorsCoadministration of GC stimulators such as riociguat with tadalafil tablets is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.4.3 Hypersensitivity ReactionsTadalafil tablet is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or CIALIS). Tadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently.

• The future may bring digital tracking (like a QR code) on the pill.
• Currently, no such markings exist on brand Cialis tablets.
• Any change to its appearance would require regulatory approval.
• Patients and doctors would be notified well in advance.
• For now, the classic yellow, oval, imprinted tablet remains standard.
• Its appearance is a fixed point in a changing pharmaceutical landscape.
• As patents expire, the brand appearance retains its recognition.
• Generics will continue to use different looks to avoid trademark issues.
• The brand pill's appearance is its lasting visual legacy.
• It is a simple object that has impacted millions of lives.
• Understanding its appearance is part of responsible medication use.

Tadalafil potentiates the hypotensive effect of nitrates.This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)]. Coadministration of GC stimulators such as riociguat with tadalafil tablets is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators. Tadalafil tablet is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or CIALIS). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with pre-existing hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD).

• Original Cialis has a distinctive bright orange, oval shape.
• They feature a logo or dose number on one side.
• The pills are coated with a smooth, shiny finish.
• Size usually around 8-14 mm in length.
• The shape is elongated oval for ease of intake.
• Markings help differentiate strength levels.
• Capsule forms are not typical; mostly solid tablets.

Since there are no clinical data on administration of tadalafil to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended. Should signs of pulmonary edema occur when tadalafil tablet is administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged ≥50 in the general population.

Color	Description	Brand Name Variations	Visual Notes
White	Most common, standard look	Cialis Classic	Smooth, glossy surface
Blue	Less common, for specific brands	Generic versions	Matte or shiny finish
Yellow	Rare, specialty formulations	N/A	Bright, vibrant appearance

An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. Other risk factors for NAION, such as the presence of "crowded" optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil.

5. A different version of tadalafil also exists

An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. Other risk factors for NAION, such as the presence of "crowded" optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitor has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

Age-Specific Patterns

Patients with conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease) are at an increased risk. Tadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Patients with pre-existing hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when cialis chewable tadalafil tablet is administered, the possibility of associated PVOD should be considered.

Transition process

When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)]. Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitor has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. Patients with conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease) are at an increased risk. Tadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Patients with pre-existing hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when cialis chewable tadalafil tablet is administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)]. Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.

4.1 Nitrates

Stop tadalafil tablets at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)]. The recommended dose of tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended.

hepatic dosing

Mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations (8.6)] . Mild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day. Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied.

Prolonged erection

Avoid use of tadalafil tablets [see Use in Specific Populations (8.7)] . Co-administration of Tadalafil Tablets in Patients on Ritonavir In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. Co-administration of Ritonavir in Patients on Tadalafil Tablets Avoid use of tadalafil tablets during the initiation of ritonavir. 4 CONTRAINDICATIONS 4.1 Concomitant Organic NitratesTadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labelling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil 40 mg was 4% compared to 5% in placebo-treated patientsIn the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity.

How to switch from Cialis to tadalafil

Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil.

• Most Cialis tablets are characterized by their bright orange color.
• The shape is typically elongated oval for swallowing ease.
• They have an imprint, like a logo or number, for identification.
• The pills are coated to prevent taste and ease digestion.
• Size varies, but generally around 8 to 14 mm in length.
• The shape is symmetrical with rounded edges.
• Some versions feature unique logos for branding purposes.

These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)].